Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Uterine sarcoma is a rare malignancy with the worst prognosis of all uterine cancers. This study evaluated the prognostic factors and treatment outcomes of patients with this disease.

Methods

A retrospective analysis was performed on 127 patients with histologically verified uterine sarcoma who were treated and followed at the Asan Medical Center (Seoul, Korea) from 1989 to 2007.

Results

Histological analyses revealed that 37 patients had endometrial stromal sarcoma, 44 had malignant mixed mullerian tumors and 46 had leiomyosarcoma. Surgical stages, as defined by the International Federation of Gynecology and Obstetrics (FIGO) system, were I in 82 patients, II in 6 patients, III in 18 patients and IV in 19 patients. All patients underwent surgical treatment and 72 patients received adjuvant therapy. The 10-year disease-free survival (DFS) rate was 30% and the 10-year overall survival (OS) rate was 48%, with a mean follow-up time of 38 months (ranging from 1 to 212 months). Adjuvant radiation and chemotherapy had limited impact on the outcome of early-stage disease. However, patients with advanced-stage disease who received adjuvant chemotherapy had significantly longer OS times. A multivariate analysis revealed that FIGO stage (P = 0.025), depth of myometrial invasion (P = 0.004), and complete cytoreduction (P = 0.030) were significantly associated with DFS, while menopausal status (P = 0.044), FIGO stage (P = 0.016), depth of myometrial invasion (P = 0.029), and lymph-vascular space invasion (LVSI) (P = 0.020) were significantly associated with OS.

Conclusions

This study suggests that complete cytoreduction is important and adjuvant chemotherapy can help achieve favorable prognoses in patients with advanced stage disease. However, postmenopausal status, advanced FIGO stage, deep myometrial invasion, and positive LVSI were associated with poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Benoit L, Arnould L, Cheynel N, Goui S, Collin F, Fraisse J et al (2005) The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol 31:434–442. doi:10.1016/j.ejso.2005.01.010

    Article  PubMed  CAS  Google Scholar 

  • Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208. doi:10.1016/j.ygyno.2003.12.029

    Article  PubMed  Google Scholar 

  • Chauveinc L, Deniaud E, Plancher C, Sastre X, Amsani F, de la Rochefordiere A et al (1999) Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments. Gynecol Oncol 72:232–237. doi:10.1006/gyno.1998.5251

    Article  PubMed  CAS  Google Scholar 

  • Coquard R, Romestaing P, Ardiet JM, Mornex F, Sentenac I, Gerard JP (1997) Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy. Bull Cancer 84:625–629

    PubMed  CAS  Google Scholar 

  • Cox DR (1972) Regression models and life tables. R Stat Soc B 34:187–220

    Google Scholar 

  • Denschlag D, Masoud I, Stanimir G, Gilbert L (2007) Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 33:91–95. doi:10.1016/j.ejso.2006.11.012

    Article  PubMed  CAS  Google Scholar 

  • Dusenbery KE, Potish RA, Argenta PA, Judson PL (2005) On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol 28:295–300. doi:10.1097/01.coc.0000156919.04133.98

    Article  PubMed  Google Scholar 

  • El Husseiny G, Al Bareedy N, Mourad WA, Mohamed G, Shoukri M, Subhi J et al (2002) Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol 25:256–260. doi:10.1097/00000421-200206000-00010

    Article  PubMed  CAS  Google Scholar 

  • Gadducci A, Romanini A (2001) Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol 22:352–357

    PubMed  CAS  Google Scholar 

  • Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A et al (1996) Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63:247–253. doi:10.1006/gyno.1996.0314

    Article  PubMed  CAS  Google Scholar 

  • Gadducci A, Cosio S, Romanini A, Genazzani AR (2008) The management of patients with uterine sarcoma: A debated clinical challenge. Crit Rev Oncol Hematol 65:129–142. doi:10.1016/j.critrevonc.2007.06.011

    Article  PubMed  Google Scholar 

  • George M, Pejovic MH, Kramar A (1986) Uterine sarcomas: prognostic factors and treatment modalities—study on 209 patients. Gynecol Oncol 24:58–67. doi:10.1016/0090-8258(86)90008-9

    Article  PubMed  CAS  Google Scholar 

  • Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL et al (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89:460–469. doi:10.1016/S0090-8258(03)00137-9

    Article  PubMed  Google Scholar 

  • Gonzalez-Bosquet E, Martinez-Palones JM, Gonzalez-Bosquet J, Garcia Jimenez A, Xercavins J (1997) Uterine sarcoma: a clinicopathological study of 93 cases. Eur J Gynaecol Oncol 18:192–195

    PubMed  CAS  Google Scholar 

  • Hempling RE, Piver MS, Baker TR (1995) Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial. Am J Clin Oncol 18:282–286. doi:10.1097/00000421-199508000-00002

    Article  PubMed  CAS  Google Scholar 

  • Kaplan EL, Meier P (1958) Nonparametric extimator from incomplete observations. J Am Stat Assoc 53:457–481. doi:10.2307/2281868

    Article  Google Scholar 

  • Kelly KL, Craighead PS (2005) Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Centre. Int J Gynecol Cancer 15:132–139. doi:10.1111/j.1048-891x.2005.15014.x

    Article  PubMed  Google Scholar 

  • Kokawa K, Nishiyama K, Ikeuchi M, Ihara Y, Akamatsu N, Enomoto T et al (2006) Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990–2003). Int J Gynecol Cancer 16:1358–1363. doi:10.1111/j.1525-1438.2006.00536.x

    Article  PubMed  CAS  Google Scholar 

  • Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D et al (2005) Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 106:1304–1308

    PubMed  Google Scholar 

  • Livi L, Andreopoulou E, Shah N, Paiar F, Blake P, Judson I et al (2004) Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 16:261–268. doi:10.1016/j.clon.2004.01.010

    CAS  Google Scholar 

  • Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL et al (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71:1702–1709

    CAS  Google Scholar 

  • Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170

    PubMed  CAS  Google Scholar 

  • Morice P, Rodrigues A, Pautier P, Rey A, Camatte S, Atallah D et al (2003) Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure. Gynecol Obstet Fertil 31:147–150. doi:10.1016/S1297-9589(03)00061-4

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC Jr, Creasman W et al (1985) Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55:1648–1653. doi:10.1002/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7

    Article  PubMed  CAS  Google Scholar 

  • Nordal RR, Thoresen SO (1997) Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer 33:907–911. doi:10.1016/S0959-8049(97)00040-3

    Article  PubMed  CAS  Google Scholar 

  • Odunsi K, Moneke V, Tammela J, Ghamande S, Seago P, Driscoll D et al (2004) Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer 14:659–664. doi:10.1111/j.1048-891X.2004.14420.x

    Article  PubMed  CAS  Google Scholar 

  • Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK (1991) Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 27:1095–1099

    Article  PubMed  CAS  Google Scholar 

  • Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C et al (1985) A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 3:1240–1245

    PubMed  CAS  Google Scholar 

  • Peters WA 3rd, Kumar NB, Fleming WP, Morley GW (1984) Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 63:550–556

    PubMed  Google Scholar 

  • Reed N, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Tateo S et al (2003) First results of a randomised trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. An EORTC-GCG study. Int J Gynecol Cancer 13:4

    Google Scholar 

  • Rovirosa A, Ascaso C, Ordi J, Abellana R, Arenas M, Lejarcegui JA et al (2002) Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys 52:1320–1329. doi:10.1016/S0360-3016(01)02808-5

    Article  PubMed  Google Scholar 

  • Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M et al (2004) Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 67:33–39. doi:10.1159/000080283

    Article  PubMed  Google Scholar 

  • Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S (1994) An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 55:229–233. doi:10.1006/gyno.1994.1282

    Article  PubMed  CAS  Google Scholar 

  • Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G et al (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 79:147–153. doi:10.1006/gyno.2000.6001

    Article  PubMed  CAS  Google Scholar 

  • Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H (2005) Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96:630–634. doi:10.1016/j.ygyno.2004.11.022

    Article  PubMed  CAS  Google Scholar 

  • Wolfson AH, Wolfson DJ, Sittler SY, Breton L, Markoe AM, Schwade JG et al (1994) A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 52:56–62. doi:10.1006/gyno.1994.1011

    Article  PubMed  CAS  Google Scholar 

  • Wu TI, Chang TC, Hsueh S, Hsu KH, Chou HH, Huang HJ et al (2006) Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol 100:166–172. doi:10.1016/j.ygyno.2005.08.010

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

The authors hereby confirm that all authors fulfill the requirements for authorship and that no potential conflicts of interest are declared.

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, #388-1 Poongnap-2 dong, Songpa-gu, Seoul, 138-736, South Korea

    Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim & Joo-Hyun Nam

Authors
  1. Jeong-Yeol Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dae-Yeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dae-Shik Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jong-Hyeok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-Man Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Young-Tak Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joo-Hyun Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joo-Hyun Nam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, JY., Kim, DY., Suh, DS. et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol 134, 1277–1287 (2008). https://doi.org/10.1007/s00432-008-0422-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0422-2

Keywords

Search

Navigation